Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. by Tiel Groenestege, W.M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/52958
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Research article
2260	 The	Journal	of	Clinical	Investigation	 	 	 http://www.jci.org	 	 	 Volume 117	 	 	 Number 8	 	 	 August 2007
Impaired basolateral sorting of  
pro-EGF causes isolated recessive  
renal hypomagnesemia
Wouter M. Tiel Groenestege,1 Stéphanie Thébault,1 Jenny van der Wijst,1 Dennis van den Berg,1 
Rob Janssen,1 Sabine Tejpar,2 Lambertus P. van den Heuvel,3 Eric van Cutsem,2  
Joost G. Hoenderop,1 Nine V. Knoers,4 and René J. Bindels1
1Department of Physiology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.  
2Digestive Oncology Unit, Department of Internal Medicine, University Hospital Gasthuisberg and Catholic University Leuven, Leuven, Belgium.  
3Department of Pediatrics and 4Department of Human Genetics, Nijmegen Centre for Molecular Life Sciences,  
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Primary	hypomagnesemia	constitutes	a	rare	heterogeneous	group	of	disorders	characterized	by	renal	or	intes-
tinal	magnesium	(Mg2+)	wasting	resulting	in	generally	shared	symptoms	of	Mg2+	depletion,	such	as	tetany	and	
generalized	convulsions,	and	often	including	associated	disturbances	in	calcium	excretion.	However,	most	
of	the	genes	involved	in	the	physiology	of	Mg2+	handling	are	unknown.	Through	the	discovery	of	a	muta-
tion	in	the	EGF	gene	in	isolated	autosomal	recessive	renal	hypomagnesemia,	we	have,	for	what	we	believe	is	
the	first	time,	identified	a	magnesiotropic	hormone	crucial	for	total	body	Mg2+	balance.	The	mutation	leads	
to	impaired	basolateral	sorting	of	pro-EGF.	As	a	consequence,	the	renal	EGFR	is	inadequately	stimulated,	
resulting	in	insufficient	activation	of	the	epithelial	Mg2+	channel	TRPM6	(transient	receptor	potential	cation	
channel,	subfamily	M,	member	6)	and	thereby	Mg2+	loss.	Furthermore,	we	show	that	colorectal	cancer	patients	
treated	with	cetuximab,	an	antagonist	of	the	EGFR,	develop	hypomagnesemia,	emphasizing	the	significance	
of	EGF	in	maintaining	Mg2+	balance.
Introduction
Magnesium (Mg2+) is established as a central electrolyte in a large 
number of cellular metabolic reactions, including DNA synthe-
sis, neurotransmission, and hormone receptor binding. It is a 
component of GTPase and a cofactor for Na,K-ATPase, adenylate 
cyclase, phosphoinositide kinases, and phosphofructokinase (1). 
Mg2+ is also important for the regulation of parathyroid hormone 
release (2, 3). Accordingly, Mg2+ deficiency (plasma Mg2+ concen-
trations below 0.70 mM) has an effect on multiple body functions. 
Symptoms of Mg2+ deficiency are mostly related to muscle dys-
functioning, such as tetany, prolonged QT interval, and cardiac 
arrhythmias (4). Children with hypomagnesemia often present 
with tetany and/or convulsions. Hypomagnesemia is a problem 
frequently observed in more than 10% of hospitalized patients and 
occurrences can be as high as 65% in intensive care patients (5). A 
long-term complication seen in many adult patients with chronic 
hypomagnesemia is chondrocalcinosis, which can lead to impair-
ment of joint function (4). Mg2+ deficiency can be secondary to 
systemic diseases (for instance, diabetes mellitus and Crohn dis-
ease) or to the use of osmotic agents, diuretics, and drugs such as 
cyclosporin and cisplatin (6). In addition, primary Mg2+ deficiency 
is observed in several monogenetic disorders. Failure of early diag-
nosis or noncompliance with treatment can be fatal or result in 
permanent neurological damage.
The plasma Mg2+ concentration is regulated within a narrow 
range by changes in urinary Mg2+ excretion in response to altered 
uptake by the intestine. Thus, the kidney plays a key role in Mg2+ 
homeostasis (4, 7). Most renal reabsorption of Mg2+ occurs in the 
proximal tubule and the thick ascending limb of the loop of Henle 
via a passive paracellular transport process, but the fine-tuning 
of the Mg2+ excretion takes place in the distal convoluted tubule 
(DCT), where Mg2+ is reabsorbed via an active transcellular trans-
port process (6, 7). Apical entry into DCT cells is mediated by the 
Mg2+-permeable channel TRPM6 (transient receptor potential cat-
ion channel, subfamily M, member 6) driven by a favorable trans-
membrane voltage (8). The mechanism of basolateral Mg2+ trans-
port into the interstitium is unknown. Mg2+ has to be extruded 
against an unfavorable electrochemical gradient, most likely by a 
Na+/Mg2+-dependent exchange mechanism and/or a Mg2+ ATPase. 
Finally, 3%–5% of the filtered Mg2+ is excreted in the urine.
Despite the critical role in Mg2+ handling, the exact mecha-
nisms of transepithelial Mg2+ transport remain obscure. Studies 
of disorders with primary hypomagnesemia are very important to 
gaining more insight into the molecular and cellular mechanisms 
that underlie Mg2+ (re)absorption. Genetic studies in families with 
hereditary renal Mg2+ wasting syndromes have identified several 
genes that are either directly or indirectly involved in active Mg2+ 
handling. In the past few years, genetic studies of inborn errors 
of the Mg2+ balance revealed several new proteins unexpectedly 
involved in transepithelial Mg2+ transport in the DCT, e.g., thia-
zide-sensitive sodium chloride cotransporter (NCC), the γ subunit 
of the Na,K-ATPase, and the previously mentioned epithelial Mg2+ 
channel, TRPM6 (9–12).
The aim of the present study was, therefore, to elucidate the 
gene defect and molecular mechanism underlying isolated reces-
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sive renal hypomagnesemia (IRH), which is characterized by renal 
Mg2+ loss. To this end, a homozygosity-based mapping strategy 
and mutation detection was performed. In addition, the molecular 
mechanism of IRH was studied in vitro using patch clamp analysis 
and in vivo using clinical studies in humans.
Results and Discussion
IRH is characterized by low serum Mg2+ levels and mental retarda-
tion. Two affected sisters, V3 and V4 (Figure 1A), displayed low 
serum Mg2+ levels (0.53–0.66 mM) in combination with urinary 
fractional excretion (FE) values of Mg2+ of 4.8% and 3.6%, respec-
tively. These values are well above an FE of 2%, indicating renal 
Mg2+ wasting as previously described (5, 13). Thus, the fact that 
the urinary excretion of Mg2+ was in the normal range while serum 
Mg2+ values were hypomagnesemic points to a diminished tubular 
Mg2+ reabsorption. Apart from hypomagnesemia, other biochemi-
cal abnormalities were not identified; in particular, there was no 
disturbance in urinary Ca2+ excretion (14). Both sisters showed 
psychomotor retardation during childhood, and presently they 
are moderately mentally retarded women who suffer from epilep-
tic seizures. The previously identified genes involved in renal Mg2+ 
handling encoding the thiazide-sensitive sodium chloride cotrans-
porter NCC (SLC12A3), paracellin-1 (CLDN16), the γ subunit of the 
NaK-ATPase (FXYD2), and the epithelial Mg2+ channel (TRPM6) 
have been excluded for these 2 affected sisters (Figure 1A) (8, 11, 
12, 15). To determine the disease locus of this consanguineous 
family, a homozygosity-based mapping strategy with a set of high-
ly polymorphic microsatellite markers spread over the genome 
was performed and followed by fine mapping. This resulted in the 
identification of a critical linkage interval with LOD score 2.66 
Figure 1
Molecular analysis of EGF. (A) Pedigree of the family in which specific members suffer from IRH. Filled symbols represent affected individuals, 
half-filled symbols are heterozygous for the mutation C3209T, and open symbols represent clinically unaffected family members not screened 
for the mutation. Slash marks indicate deceased individuals, and double lines show consanguinity. (B) Schematic representation of the critical 
interval between polymorphic markers D4S2623 and D4S1575 on chromosome 4q and the intron-exon structure of the EGF gene, depicting 
the identified mutation. The position of the polymorphic markers is indicated by vertical bars. The horizontal arrow below the schematical boxed 
representation of EGF depicted between the polymorphic markers indicates the localization and orientation of the EGF gene. Cen, centromeric; 
tel, telomeric. (C) Genomic mutation sequence analysis of EGF in wild-type, heterozygous, and affected individuals. The mutated nucleotide and 
resulting amino-acid change is shown under the affected individual’s sequence. The black bar under that sequence indicates the mutated codon. 
The black bars under the sequences of the WT and heterozygous specify codon 1070 of EGF. The affected individuals both have a homozygous 
mutation C3209T in exon 22, resulting in the amino acid substitution P1070L. (D) Schematic model of pro-EGF, which resides as a type I mem-
brane protein at the plasma membrane. The position of the P1070L mutation is depicted. (E) Sequence homology analysis of juxtamembrane 
domain and flanking residues. P1070 is strongly conserved among different species and forms the second proline of a basolateral PXXP sorting 
motif. The indicated colors represent functional conservation of the amino acids: red, small plus hydrophobic; blue, acidic; magenta, basic; green, 
hydroxyl plus amine plus basic; gray, others. TM, transmembrane domain.
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(P < 0.004) on chromosome 4 of 18.4 cM between markers D4S2623 
and D4S1575 (Figure 1B). A search for candidate genes within this 
region revealed the EGF gene, which was considered a highly rel-
evant positional candidate since it had previously been linked to 
electrolyte homeostasis (16).
We sequenced EGF in the affected individuals (Figure 1A) and 
identified the homozygous mutation C3209T in exon 22, which 
cosegregated with the disorder and was absent in 126 ethnically 
matched control chromosomes (Figure 1C). The mutation caused 
the substitution of the highly conserved proline 1070 within the 
cytoplasmic tail of pro-EGF by leucine (P1070L) (Figure 1, D and 
E). We found that both parents and the 2 unaffected sisters (Fig-
ure 1A) of this Dutch family were heterozygous for the mutation. 
Furthermore, the paternal aunt was heterozygous for the muta-
tion whereas her 2 children (Figure 1A) exhibited the homozygous 
wild-type genotype (Figure 1, A and C).
The EGF gene consists of 24 exons encoding a large type I mem-
brane–anchored precursor protein of 1,207 amino acid residues 
that exists as a membrane-bound molecule, which is proteolyti-
cally cleaved into pro-EGF to finally generate the 53–amino acid 
peptide hormone EGF (17). EGF has a profound effect on cell dif-
ferentiation in vivo and is a potent mitogenic factor for a variety 
of cultured cells of both ectodermal and mesodermal origin (18). 
EGF belongs to the EGF-like family of growth factors, which bind 
with high affinity to the EGFR. Other members of this family are 
TGF-α, amphiregulin, heparin-binding EGF-like growth factor, 
betacellulin, and epiregulin (19–21). These membrane-anchored 
growth factor precursors are characterized by the fact that they are 
biologically active at the cell surface although they can be proteo-
lytically cleaved to release soluble, diffusible factors (19–21).
To study the tissue distribution of pro-EGF and EGFR, we per-
formed RT-PCR on various human tissues (Figure 2A). For EGF, 
PCR amplification products were detected in, e.g., kidney, salivary 
gland, cerebrum, and prostate, whereas no expression was detected 
in the adrenal gland, liver, cerebellum, and placenta. The EGFR 
showed a ubiquitous expression pattern since all tissues tested were 
positive by RT-PCR analysis (Figure 2A). Immunohistochemistry 
on rat kidney sections showed that EGF is consistently coex-
pressed with NCC, a marker of the DCT (22) (Figure 2B). Inter-
estingly, the immunopositive staining is mainly localized along 
the apical domain in DCT. Coffey and coworkers demonstrated 
that human pro-EGF overexpressed in Madin-Darby canine kid-
ney (MDCK) cells is delivered equally to the apical and basolateral 
membrane but is found predominantly at the apical membrane 
domain (23). They proposed that preferential ectodomain cleavage 
at the basolateral surface explains the apparent apical localization 
of pro-EGF. Sack and Talor provided evidence for the existence 
of specific binding sites in tubular basolateral membranes, sug-
gesting a physiologic role of EGF in the kidney (24). In the kidney, 
the EGFR was detected in glomerular endothelial cells, peritubular 
capillaries, and arteriolar walls as well as along the thick ascend-
ing limb of Henle loop and DCT (25, 26). Immunohistochemical 
analysis revealed that the EGFR was located particularly along the 
basolateral membrane of the tubular cells. The DCT reabsorbs 
approximately 10% of the filtered Mg2+ load, and the reabsorption 
rate in this segment defines the final urinary Mg2+ excretion, as vir-
tually no reabsorption takes place beyond this section (1). In kid-
ney, the epithelial Mg2+ channel TRPM6 is specifically expressed 
in DCT, where it forms the rate-limiting step of epithelial Mg2+ 
transport (8). Thus, pro-EGF and TRPM6 are both predominantly 
Figure 2
Expression profiling of EGF and EGFR. 
(A) The expression of EGF and EGFR 
mRNA was determined by RT-PCR on 
various human tissues. Signals for EGF 
were detected in, e.g., kidney, salivary 
gland, prostate, and cerebrum whereas 
no signals were detected in the adrenal 
gland, cerebellum, liver, lung, and pla-
centa. The EGFR showed a ubiquitous 
expression pattern since PCR amplifica-
tion products were obtained in all tissues 
tested. hEGF, human EGF; hEGFR, 
human EGFR. (B) Immunohistochemical 
analysis of EGF (green) and thiazide-
sensitive sodium chloride cotransporter 
(NCC, red) in rat kidney sections (upper 
panel, overview of a cortical region; 
lower panel, magnified image of an 
immunopositive tubule). EGF colocal-
ized with NCC, a marker for the DCT. 
Original magnification, ×180 (B, top pan-
els); ×360 (B, bottom panels).
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expressed in DCT, the main site of active renal Mg2+ reabsorption 
(1, 16, 17, 27). To determine whether EGF can regulate the activ-
ity of TRPM6, human embryonic kidney 293 (HEK293) cells were 
transiently transfected with TRPM6 and treated for 30 minutes 
with EGF (10 nM), resulting in increased channel activity (Fig-
ure 3A). Western blot analysis demonstrated endogenous expres-
sion of EGFR in these HEK293 cells (data not shown). EGF dose 
dependently stimulated TRPM6 activity with half maximal effec-
tive concentration of 1.7 nM, an apparent affinity that is in the 
physiological range as reported previously (Figure 3B) (24).
Previous in vivo studies showed that the predominant form 
of EGF released from epithelial cells is the high-molecular mass 
160–170 kDa EGF, as found at high concentrations in serum, 
urine, and milk (28, 29). To investigate the functional effect of 
the identified mutation, HEK293 cells were transfected with wild-
type or mutant pro-EGF and after 2 days their supernatant was 
collected. TRPM6-expressing HEK293 cells were subsequently 
incubated for 30 minutes with these preconditioned media and 
analyzed for channel activity using the patch clamp technique. 
Interestingly, the supernatant obtained from mutant pro-EGF–
expressing HEK293 cells failed to stimulate TRPM6 activity 
whereas a significant channel activation was observed with the 
wild-type EGF–containing supernatant (Figure 3C). Quantifica-
tion of EGF in both supernatants using ELISA indicated that the 
secretion of mutant pro-EGF is impaired (Figure 3D).
To demonstrate that the observed stimulatory effects are due to 
EGFR activation, a preincubation with cetuximab was performed. 
This IgG human/mouse chimeric monoclonal antibody competi-
tively inhibits the activation of the EGFR. It binds externally to 
the EGFR to block binding of the ligand and subsequent signal 
transduction mediated via the receptor-associated tyrosine kinase 
and prevents phosphorylation of the EGFR and other downstream 
Figure 3
Electrophysiological analysis of pro-EGF and pro-EGF–P1070L on TRPM6 channel activity. (A) Average time course of outward (at +80 mV) 
current densities from HEK293 cells transfected with TRPM6 in control conditions (open circles) and after EGF treatment (30 minutes, 10 nM, 
filled circles) in comparison with mock-transfected cells without EGF treatment (triangles) and after EGF stimulation (filled triangles). n = 17–20. 
(B) Dose-response curve of EGF-induced current in TRPM6-transfected HEK293 cells indicating half maximal effective concentration of 1.7 nM. 
 n = 11–14. (C) Histogram presenting the current densities at +80 mV of TRPM6-transfected cells (200 seconds after establishment of the whole-
cell configuration) treated with mock (mock), pro-EGF (EGF WT) or pro-EGF–P1070L (EGF-P1070L) supernatant. All treatments were performed 
for 30 minutes at 37°C. White bars indicate experimental conditions in which HEK293 cells were transfected with mock DNA whereas black 
bars indicate HEK293 cells transfected with TRPM6. Asterisk indicates significance in comparison with nontreated TRPM6-transfected cells. 
P = 0.024; n = 6. (D) Supernatants of mock-, pro-EGF–, or pro-EGF–P1070L–transfected HEK293 cells were analyzed by ELISA. Asterisk indi-
cates mock and pro-EGF–P1070L supernatant were significantly different from EGF supernatant. P = 0.006; n = 4. (E) Histogram summarizing 
the current density (pA/pF) at +80 mV (200 seconds after break-in) of HEK293 cells treated with the apical or basolateral supernatant of MDCK 
cells stably transfected with either wild-type pro-EGF, pro-EGF–P1070L, or mock DNA (30 minutes, 37°C). White bars indicate experimental 
conditions in which HEK293 cells were transfected with mock DNA whereas black bars indicate HEK293 cells transfected with TRPM6. Crosses 
indicate significance in comparison with the mock treatment at the apical side (wild-type pro-EGF apical, P = 0.0001, n = 6; pro-EGF–P1070L 
apical, P = 0.029, n = 6), and pound symbol represents significance in comparison with the mock treatment at the basolateral side (wild-type 
pro-EGF basolateral P = 0.031, n = 6). (F) Schematic model illustrating how pro-EGF–P1070L mutation results in IRH. The pro-EGF–P1070L 
mutation leads to impaired basolateral sorting of pro-EGF, resulting in abrogated stimulation of the EGFR localized at the basolateral membrane. 
Activation of the EGFR in DCT by EGF is necessary to prevent renal Mg2+ wasting by stimulation of the epithelial Mg2+ channel TRPM6.
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proteins in the signal transduction cascade (30). The stimulatory 
effect of the supernatant collected from pro-EGF–expressing 
HEK293 cells on TRPM6 was significantly inhibited by preincuba-
tion for 1 hour with cetuximab (191 ± 22 pA/pF, 491 ± 62 pA/pF, 
and 286 ± 48 pA/pF for TRPM6-expressing HEK293 cells mea-
sured at +80 mV and treated with mock supernatant, EGF super-
natant, or EGF supernatant plus cetuximab, respectively; P < 0.05, 
n = 6). Thus, the stimulatory effect of the supernatant on TRPM6 
activity is due to direct activation of the EGFR.
As outlined above, the localization of EGFR is restricted to the 
basolateral membrane whereas pro-EGF is present at both the api-
cal and basolateral membranes (23). This prompted us to investi-
gate in detail the cellular metabolism of pro-EGF. Recently, several 
basolateral sorting motifs were identified, including the sequence 
motif PXXP (with X being an arbitrary amino acid), determining 
the targeting of proteins to the basolateral membrane in MDCK 
cells (31). Our mutation substitutes the second highly conserved 
proline in the cytoplasmic 1067PKNP1070 motif into a leucine 
(Figure 1D). We hypothesized that this mutation 
results in improper trafficking of pro-EGF, which 
prevents an adequate secretion of the hormone into 
the circulation. Since EGFR is only localized basolat-
erally, the mutation should prevent the ligand from 
reaching its receptor. Interestingly, He and coworkers 
have shown previously that a 22–amino acid sequence 
in the EGFR juxtamembrane domain contains auton-
omous sorting information necessary for basolateral 
localization of the receptor in MDCK cells (31). This 
sorting motif contains a polyproline core comprising 
residues P667 and P670 (667PXXP670). Site-directed 
mutations at P667 and P670 were associated with 
impaired basolateral delivery of the EGFR.
To determine the effect of the mutation on the sort-
ing of pro-EGF in polarized epithelial cells, MDCK 
cells stably expressing either wild-type or mutant pro-
EGF were grown on semipermeable filter supports 
until they reached confluency. After 2 days, media of 
the basolateral and apical compartment were collected 
individually. Next, HEK293 cells expressing TRPM6 
were treated with the collected preconditioned media 
of wild-type pro-EGF, mutant pro-EGF, or mock-
expressing cells. Equal stimulation of TRPM6 chan-
nel activity was observed when the cells were incu-
bated with the apically collected media of wild-type or 
mutant pro-EGF–expressing MDCK cells (Figure 3E). 
However, stimulation of TRPM6 channel activity was 
only observed with basolaterally collected wild-type 
pro-EGF medium, not with the basolateral mutant 
pro-EGF media (Figure 3E). Of note, the apically and 
basolaterally collected mock medium did not affect 
TRPM6 activity. These observations suggest that the 
basolateral release of mutant pro-EGF is diminished, 
seriously hampering the EGF-dependent activation of 
the basolaterally localized EGFR (Figure 3F).
Clinical trials directed to the treatment of patients 
with colorectal cancer have demonstrated that cetux-
imab is synergistic with chemotherapy for these 
patients (32). We observed that serum Mg2+ levels 
gradually decreased in all studied colorectal cancer 
patients on cetuximab treatment (Figure 4A). This is 
in line with a recent report showing that a significant number of 
similarly treated patients developed hypomagnesemia (30). Our 
patients treated with cetuximab displayed an FE of Mg2+ of 5.1%, 
which is inappropriately high given their hypomagnesemia (Figure 
4B). As previously established by Agus (5), an FE of Mg2+ above 2% 
in the presence of hypomagnesemia indicates renal Mg2+ loss.
The 2 affected sisters with IRH exhibited a similar relatively high 
Mg2+ excretion profile (Figure 4B). The urinary Mg2+ patterns of 
the patients treated with EGFR antibodies, the patients described 
in our Dutch family, and patients with hypomagnesemia with sec-
ondary hypocalcemia (HSH; OMIM 602014) (11, 12) were identi-
cal and suggest mutual defects in renal TRPM6 activity. Indeed, 
preincubation with cetuximab abolished the stimulatory effect 
of EGF on TRPM6 activity as shown by patch clamp analysis of 
TRPM6-expressing HEK293 cells (Figure 4C). Taken together, 
these data strongly suggest a pivotal role for EGFR signaling in 
the maintenance of normal Mg2+ balance and indicate TRPM6 as 
a critical link between EGFR inhibition and IRH.
Figure 4
Effect of cetuximab treatment on Mg2+ balance and TRPM6 activity. (A) Changes 
in serum Mg2+ levels from baseline over time during cetuximab therapy are shown 
for 20 colorectal cancer patients. Solid lines represent individual linear regression 
lines of the data points for each individual patient. Open symbols denote end of 
treatment. (B) Cetuximab treatment leads to renal Mg2+ loss and hypomagnesemia. 
Serum samples and urine (over a 24-hour period) was collected from 8 patients at 
baseline in normomagnesemic conditions (open circles), 12 patients on cetuximab 
treatment in hypomagnesemic conditions (filled circles), and patients (V3, V4) with 
IRH (triangles), then analyzed for FE of Mg2+. FE Mg2+ was plotted against the serum 
Mg2+ concentrations for the tested individuals. Hypomagnesemia in combination with 
an inappropriately high excretion of Mg2+ was observed in patients with the P1070L 
mutation as well as in individuals treated with cetuximab. Large circles represent the 
averaged values of patients on cetuximab treatment (filled) and patients at baseline 
in normomagnesemic conditions (open). Asterisk indicates a significant difference in 
serum (Mg2+) compared with that in control patients. P = 0.001; n = 8–12. (C) Histo-
gram depicting the current densities at +80 mV of TRPM6-transfected cells that were 
exposed for 30 minutes to EGF, cetuximab, or EGF in combination with cetuximab. 
Cross indicates a significant difference compared with nontreated (CTRL) HEK293-
TRPM6 cells. P < 0.026; n = 6.
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Through the discovery of an EGF mutation in IRH, we have for 
the first time, to our knowledge, identified a magnesiotropic hor-
mone crucial for total body Mg2+ balance that directly stimulates 
renal tubular Mg2+ reabsorption via activation of the epithelial 
Mg2+ channel TRPM6. Moreover, it raises the question of whether 
EGF plays a role in mental development since our IRH patients 
(Figure 1A) are mentally retarded. EGF is present in cerebrospi-
nal fluid, and EGF mRNA has been detected in the developing 
brain of various species. Furthermore, EGF is a well-known neu-
rotrophic factor regulating the development of various neuronal 
cells (33). Futamura et al. reported that serum EGF levels were 
markedly decreased in schizophrenic patients and suggested that 
EGF might provide a link between impaired EGF signaling and 
the pathology/etiology of schizophrenia (34). An association 
between an EGF polymorphism and schizophrenia has been sug-
gested although data from several studies are conflicting (35, 36). 
Interestingly, in our Dutch family with IRH, 1 unaffected, EGF 
P1070L–carrier sister (Figure 1A) suffers from schizophrenia, and 
2 brothers and 1 sister of the carrier mother (Figure 1A) are known 
to have cluster A (Diagnostic and statistical manual of mental disorders, 
fourth edition, text revision) personality disorders. In addition, 
EGF could be involved in Mg absorption in the intestine, a site 
that also expresses TRPM6. If not, please revise sentence. Future 
therapeutic intervention might be able to treat hypo- and hyper-
magnesemia by regulating EGFR activity.
Methods
Statistics. In all experiments, data are expressed as mean ± SEM. Overall sta-
tistical significance was determined by ANOVA. Where differences between 
the means of 2 groups were significant, they were analyzed by pairwise com-
parison using Scheffe’s method. For the statistical analysis in Figure 4B, an 
unpaired Student’s t test was performed. P < 0.05 was considered significant. 
Statistical analysis was performed using SPSS software 12.0 (SPSS).
Subjects. Informed consent was obtained from the parents and unaffected 
daughters of the family in this study. The parents gave proxy consent for 
the 2 affected daughters in this study. In this family, 2 Dutch sisters suf-
fered from primary renal Mg2+ loss associated with normocalciuria. These 
women are the offspring of a consanguineous mating, and since both par-
ents did not display this disorder, the inheritance pattern was likely to be 
autosomal recessive. The clinical data of this family have previously been 
described in detail by Geven et al. (14). In short, 2 patients of this family, 
V3 and V4, had serum Mg2+ levels of 0.53 mM and 0.56 mM and urinary 
Mg2+ values of 3.9 mmol/24 h and 3.7 mmol/24 h, respectively. Given the 
low serum Mg2+ levels, urinary Mg2+ excretion was relatively high, indicat-
ing a renal Mg2+ reabsorption defect. Both patients suffer from epileptic 
seizures that started in their first year of life and are controlled by conven-
tional antiepileptic drugs. During childhood, they showed psychomotor 
retardation, and they are presently moderately mentally retarded women. 
Serum and urinary Ca2+ were in the normal range, as were serum Na+, K+, 
Cl–, HCO3–, and blood pH values. In both patients, plasma renin activity, 
plasma aldosterone, and parathyroid hormone concentrations were in the 
normal range. Blood was collected for genotyping from the parents, both 
affected and both unaffected daughters, the sister of the father, and the 
sister’s 2 unaffected children.
Mutation analysis. We extracted DNA using standard protocols. The exons 
of the EGF gene were amplified separately from genomic DNA, using the 
primers listed in Supplemental Table 1 (supplemental material available 
online with this article; doi:10.1172/JCI31680DS1). PCR products were 
purified with QIAGEN PCR Purification Kit according to the manufac-
turer’s protocol, and products were sequenced using the same primers. 
Mutation analysis of the EGF gene was performed by forward sequencing 
of the coding regions of the gene of the youngest affected family member. 
Forward and reverse sequencing of exon 22 was subsequently performed 
on all family members.
Subjects with colorectal cancer treatment. We prospectively studied consecu-
tive patients with metastatic colorectal cancer for which treatment with 
cetuximab was initiated at the University Hospital Gasthuisberg (Leuven, 
Belgium). Most patients were included in phase II or III trials. Cetuximab 
was kindly donated by Merck KGaA. Informed consent was obtained from 
all subjects investigated in this study.
Calculation of FEMg. The FEMg was calculated using the following formula:
Equation 1
U and P refer to the urine and serum concentrations of Mg2+ (Mg) and cre-
atinine (Cr). Serum Mg2+ concentration was multiplied by 0.7 since only 
approximately 70% of the circulating Mg2+ was unbound by albumin and 
therefore able to be filtered across the glomerulus.
Expression profiling. PCRs were performed in 50 μl reaction volumes con-
taining 1 μl of cDNA, 10 pmol of each primer (Supplemental Table 2), 
2.5 mM MgCl2, 200 μM of each deoxyribonucleotide triphosphate (dATP, 
dTTP, dCTP, and dGTP), and 0.5 U of Taq polymerase. PCRs had an initial 
denaturation stage of 1 minute at 95°C, followed by 39 cycles of 30 sec-
onds at 95°C, 1 minute at 55°C, 1 minute at 72°C, and a final extension 
step at 72°C for 10 minutes.
Immunohistochemistry. Staining of rat kidney sections for NCC and EGF 
was performed on 7-μm cryosections of periodate-lysine paraformaldehyde–
fixed kidney samples. Sections were stained with affinity-purified anti-NCC 
(1:200) and affinity-purified rabbit anti-EGF (1:100) (Calbiochem; EMD 
Biosciences). Images were made with a Bio-Rad MRC 1000 laser scanning 
confocal imaging system using a ×60 oil-immersion objective.
Linkage analysis. Samples of peripheral EDTA blood were collected from 
each person, and genomic DNA was isolated using standard procedures. 
Homozygosity mapping was performed with a genome-wide set of 400 
evenly distributed microsatellite markers (LMS-MD10 2.5; Applied Bio-
systems), with an average intermarker distance of 10 cM, on the basis of 
Marshfield genetic maps (http://research.marshfieldclinic.org/genetics/
GeneticResearch/compMaps.asp). The average heterozygosity of these 
markers was 0.76. Five additional markers, D4S1570, D4S2623, D4S2392, 
D4S1615, and D4S422, were selected for fine mapping purposes from the 
public databases on chromosome 4 (http://research.marshfieldclinic.org/
genetics/GeneticResearch/data/Maps/Map4.txt and http://genome.ucsc.
edu/cgi-bin/hgGateway. The analysis of the markers was according to the 
protocol provided for the LMS-MD10 version 2.5 with some small modifi-
cations. PCRs were performed in 10 μl reaction volumes containing 40 ng 
of genomic DNA, 5 pmol of each primer, 2.5 mM MgCl2, 250 μM dATP, 
dTTP, dCTP, and dGTP each, 10 mM Tris/HCl (pH 8.3), 50 mM KCl, and 
0.4 U of Taq polymerase (AmpliTaq TM Gold; Applied Biosystems). PCRs 
had an initial denaturation stage of 12 minutes at 95°C, followed by 10 
cycles of 15 seconds at 94°C, 15 seconds at 55°C, and 30 seconds at 72°C, 
then 22 cycles of 15 seconds at 89°C, 15 seconds at 55°C, and 30 seconds 
at 72°C, and a final extension step at 72°C for 10 minutes. Reactions 
for each marker were performed separately, with products being pooled 
into size-specific sets before typing. Markers were typed on an ABI 3100 
sequencer (Applied Biosystems) using GeneMapper 4.0 software (Applied 
Biosystems). Allele binning was performed with the Excel 2000 (Microsoft) 
macro linkage designer developed by van Camp and coworkers (37), and 
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we checked Mendelian inheritance of alleles with PedCheck 1.0 software 
(http://watson.hgen.pitt.edu) (38). Multipoint LOD scores were calculated 
with the GeneHunter, version 2.1 release 5, program in the easyLINKAGE 
software package (39).
Constructs. The full-length EGF precursor in vector plasmid SAD (pSAD) 
was kindly provided by G.I. Bell (17) (University of Chicago, Chicago, Illi-
nois, USA). The full-length EGF precursor P1070L mutant was obtained 
by in vitro mutagenesis of the pSAD-EGF vector according to the protocol 
described by the manufacturer (Invitrogen). The construct was verified by 
DNA sequence analysis. To generate plasmid CB7 constructs for the stable 
expression of the full-length EGF precursor and the P1070L mutant in 
MDCK type I cells, PCR was performed on the pSAD-EGF and pSAD-EGF–
P1070L constructs, respectively, using Pyrococcus furiosus DNA polymerase 
according to the manufacturer’s protocol (Stratagene). Primers used were 
5′-CGGGGTACCGCCACCATGCTGCTCACTCTTATCATTC-3′ and 
5′-CGCTCTAGAGTCACTGAGTCAGCTCCATTTG-3′. PCR products were 
cloned into the plasmid CB7 vector using the restriction enzymes KpnI and 
XbaI and verified by DNA sequence analysis.
Electrophysiology. The bicistronic expression vector pCINeo-IRES-GFP 
containing the full-length open reading frames of N terminally HA-
tagged human TRPM6 (GenBank accession number NM_017662) was 
used to coexpress human TRPM6 and enhanced GFP in HEK293 cells. 
HEK293 cells were grown in DMEM (BioWhittaker) containing 10% 
(v/v) fetal calf serum, 2 mM l-glutamine, and 10 μg/ml Ciproxin at 37°C 
in a humidity-controlled incubator with 5% (v/v) CO2. Cells were tran-
siently transfected with the respective constructs using Lipofectamine 
2000 (Invitrogen), as described previously (40), and electrophysiological 
recordings were performed 48 hours after transfection. Transfected cells 
were identified by their green fluorescence when illuminated at 480 nm. 
Nontransfected (GFP-negative) cells from the same batch were used as 
controls. Patch clamp experiments were performed in the tight seal whole-
cell configuration at room temperature (20–25°C) using an EPC-10 patch 
clamp amplifier computer controlled by PatchMaster Classic 1.20 soft-
ware (HEKA Elektronik). Currents were digitized at 10 kHz and digitally 
filtered at 2.9 kHz. Patch pipettes had resistances between 2 and 5 MW 
after filling with the standard intracellular solution. Cells were held at 
0 mV, and voltage ramps of 200 ms duration ranging from –100 to +100 
mV were applied every 2 seconds. Extracting the current amplitudes at 
+80 mV from individual ramp current records provided an assessment 
of the temporal development of membrane currents. Current densities 
were obtained by normalizing the current amplitude to the cell membrane 
capacitance. The time course of current development was determined by 
measuring the current at +80 mV. Step protocols were applied from hold-
ing potentials of 0 mV and consisted of 400-ms steps to –100 to +100 mV 
(increment of 20 mV). The standard pipette solution contained 150 mM 
NaCl, 10 mM EDTA, and 10 mM HEPES/NaOH (pH 7.2). Extracellular 
solutions contained 150 mM NaCl and 10 mM HEPES/NaOH (pH 7.4) 
supplemented with 1 mM CaCl2. The osmolarity of the solutions was 
adjusted to 300–310 mOsm/kg with mannitol.
Pretreatment with EGF, preconditioned media, and cetuximab. The effect 
of EGF on TRPM6 activity in HEK293 cells transiently transfected with 
TRPM6 was measured after a 30-minute preincubation with 10 nM mouse 
EGF (Sigma-Aldrich) in DMEM (modified as described above) or the pre-
conditioned medium. Cetuximab pretreatment for 1 hour with 2 μg/ml in 
DMEM (modified as described above) was performed prior to treatment 
with EGF or preconditioned medium. Subsequently, cells were analyzed by 
the patch clamp technique as described above.
Generation of an MDCK cell line stably expressing pro-EGF and pro-EGF–
P1070L. MDCK type I cells (41) were grown in DMEM containing 5% 
(v/v) FCS (HyClone), 13 mM NaHCO3, 2 mM l-glutamine, and 10 μg/ml 
ciproxin (Bayer) at 37°C in a humidity-controlled incubator with 5% 
(v/v) CO2. For stable transfection of MDCK cells, 25 μg circular DNA 
was transfected using the Ca2+-phosphate precipitation technique (42). 
Cells were trypsinized 24 hours after transfection, seeded on Petri dishes, 
and cultured in DMEM containing 75 μg/ml hygromycin B (Invitrogen). 
Between 10 and 14 days after transfection, individual colonies were 
selected by means of cloning rings and expanded. Total RNA was extract-
ed from each colony that had been grown until confluent in a 24-well 
culture plate using TRIzol Total RNA Isolation Reagent (Invitrogen) 
according to the manufacturer’s protocol. The obtained RNA was sub-
jected to DNase treatment (Promega) to prevent genomic DNA contami-
nation. Thereafter, 1.5 μg of RNA was reverse transcribed by Moloney 
Murine Leukemia Virus Reverse Transcriptase (Invitrogen) as described 
previously (43). The cDNA was used to determine pro-EGF expression 
with the primers described in Supplemental Table 2. MDCK cells stably 
expressing plasmid CB7–EGF, plasmid CB7–EGF–P1070L, or empty vec-
tor (5 clones of each) were used to seed 10 24-mm Transwell filter wells 
of each condition (Corning Inc.). We seeded 1.5 × 105 cells/cm2 on perme-
able filter supports; these were grown for 4 days until they reached con-
fluency and an electrical resistance of greater than 2,400 Ω·cm2. Next, the 
media were replaced by DMEM medium as described below but without 
FCS and harvested after 2 days.
Transfection of HEK293 cells. HEK293 cells were transiently transfected 
with pSAD-EGF, pSAD-EGF–P1070L, or empty-vector pCINeo-IRES-GFP 
cDNA using polyethylenimine (Polysciences Inc.). Six million cells were 
seeded on a petri dish (57 cm2) (10 plates per vector) in a total volume of 
5 ml DMEM. After 3 hours, the cells were transfected. The transfection 
mix for each plate consisted of 15 μg cDNA and 90 μl polyethylenimine 
(1 μg/μl) in a total volume of 500 μl Opti-MEM (Invitrogen). The transfec-
tion mix was incubated for 20 minutes at room temperature. Subsequently, 
the transfection mix was added to the cells and incubated overnight. After 
1 day of transfection, the culture media was replaced by 8 ml DMEM medi-
um as described above but without FCS.
Collection and concentration of conditioned culture media. Two days after 
replacement of the medium of HEK293 and MDCK cells, the FCS-free 
culture media was collected and proteinase inhibitors were added (1 mM 
PMSF, 1 μg/ml pepstatin A, and 10 ng/ml leupeptin). Subsequently, the 
collected FCS-free culture media of HEK293 cells with added proteinase 
inhibitors was concentrated 400 times using Centriprep YM-3 followed 
by Microcon YM-3 (Millipore). Prior to concentration of the collected 
HEK293 medium, 2 ml of the collected FCS-free culture medium was kept 
separately and used for patch clamp analysis.
Human EGF ELISA. EGF concentrations were determined in 400 times con-
centrated culture supernatant by using Centriprep columns and a human 
EGF ELISA kit according the manufacturer’s protocol (RayBiotech Inc.).
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